93 related articles for article (PubMed ID: 10366470)
1. Expression of tenascin in human cervical cancer--association of tenascin expression with clinicopathological parameters.
Pilch H; Schäffer U; Schlenger K; Lautz A; Tanner B; Höckel M; Knapstein PG
Gynecol Oncol; 1999 Jun; 73(3):415-21. PubMed ID: 10366470
[TBL] [Abstract][Full Text] [Related]
2. Overexpression of the alpha v beta 6 integrin in cervical squamous cell carcinoma is a prognostic factor for decreased survival.
Hazelbag S; Kenter GG; Gorter A; Dreef EJ; Koopman LA; Violette SM; Weinreb PH; Fleuren GJ
J Pathol; 2007 Jul; 212(3):316-24. PubMed ID: 17503414
[TBL] [Abstract][Full Text] [Related]
3. Value of tenascin-C content and association with clinicopathological parameters in uterine cervical lesions.
Buyukbayram H; Arslan A
Int J Cancer; 2002 Aug; 100(6):719-22. PubMed ID: 12209613
[TBL] [Abstract][Full Text] [Related]
4. Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma.
Leins A; Riva P; Lindstedt R; Davidoff MS; Mehraein P; Weis S
Cancer; 2003 Dec; 98(11):2430-9. PubMed ID: 14635078
[TBL] [Abstract][Full Text] [Related]
5. EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer.
Ju XZ; Yang JM; Zhou XY; Li ZT; Wu XH
Clin Cancer Res; 2008 Jan; 14(2):494-501. PubMed ID: 18223224
[TBL] [Abstract][Full Text] [Related]
6. Tenascin-A marker for the malignant potential of preinvasive breast cancers.
Goepel C; Buchmann J; Schultka R; Koelbl H
Gynecol Oncol; 2000 Dec; 79(3):372-8. PubMed ID: 11104607
[TBL] [Abstract][Full Text] [Related]
7. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis.
Jeschke U; Mylonas I; Shabani N; Kunert-Keil C; Schindlbeck C; Gerber B; Friese K
Anticancer Res; 2005; 25(3A):1615-22. PubMed ID: 16033070
[TBL] [Abstract][Full Text] [Related]
8. The possible role of p53 and bcl-2 expression in cervical carcinomas and their premalignant lesions.
Dimitrakakis C; Kymionis G; Diakomanolis E; Papaspyrou I; Rodolakis A; Arzimanoglou I; Leandros E; Michalas S
Gynecol Oncol; 2000 Apr; 77(1):129-36. PubMed ID: 10739702
[TBL] [Abstract][Full Text] [Related]
9. Enhanced tenascin expression in cervical and vulvar koilocytotic lesions.
Tiitta O; Wahlström T; Paavonen J; Linnala A; Sharma S; Gould VE; Virtanen I
Am J Pathol; 1992 Oct; 141(4):907-13. PubMed ID: 1384340
[TBL] [Abstract][Full Text] [Related]
10. Osteopontin expression correlates with invasiveness in cervical cancer.
Song JY; Lee JK; Lee NW; Yeom BW; Kim SH; Lee KW
Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):434-8. PubMed ID: 19694703
[TBL] [Abstract][Full Text] [Related]
11. Tenascin-C expression and its prognostic significance in colorectal cancer.
Lundin M; Nordling S; Lundin J; Haglund C
Oncology; 2007; 72(5-6):403-9. PubMed ID: 18196927
[TBL] [Abstract][Full Text] [Related]
12. Peritumoral lymphatic vessel density and vascular endothelial growth factor C expression in early-stage squamous cell carcinoma of the uterine cervix.
Gombos Z; Xu X; Chu CS; Zhang PJ; Acs G
Clin Cancer Res; 2005 Dec; 11(23):8364-71. PubMed ID: 16322297
[TBL] [Abstract][Full Text] [Related]
13. [The expression of matrix metalloproteinase-2 and -9 in cervical cancer and a study of their relationship].
Ouyang YW; Peng ZL; Yao XY; Liu SL; He YD
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 May; 35(3):330-3. PubMed ID: 15181827
[TBL] [Abstract][Full Text] [Related]
14. p53 and p21 expression in precancerous lesions and carcinomas of the uterine cervix: overexpression of p53 predicts poor disease outcome.
Huang LW; Chou YY; Chao SL; Chen TJ; Lee TT
Gynecol Oncol; 2001 Nov; 83(2):348-54. PubMed ID: 11606096
[TBL] [Abstract][Full Text] [Related]
15. [Tenascin-C expression in human breast tumors].
Tökés AM; Kulka J
Orv Hetil; 2003 Sep; 144(39):1901-7. PubMed ID: 14598568
[TBL] [Abstract][Full Text] [Related]
16. Changes in tenascin-C isoform expression in invasive and preinvasive breast disease.
Adams M; Jones JL; Walker RA; Pringle JH; Bell SC
Cancer Res; 2002 Jun; 62(11):3289-97. PubMed ID: 12036947
[TBL] [Abstract][Full Text] [Related]
17. [Relationship between expression of matrix metalloproteinase (MMP-9) and tumor angiogenesis, cancer cell proliferation, invasion, and metastasis in invasive carcinoma of cervix].
Jiang ZQ; Zhu FC; Qu JY; Zheng X; You CL
Ai Zheng; 2003 Feb; 22(2):178-84. PubMed ID: 12600296
[TBL] [Abstract][Full Text] [Related]
18. Differential distribution of tenascin in the normal, hyperplastic, and neoplastic breast.
Howeedy AA; Virtanen I; Laitinen L; Gould NS; Koukoulis GK; Gould VE
Lab Invest; 1990 Dec; 63(6):798-806. PubMed ID: 1701508
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of matrix metalloproteinase-2 in cancer of uterine cervix: a semiquantitative study of immunoreactivities using tissue array.
Wang PH; Ko JL; Tsai HT; Yang SF; Han CP; Lin LY; Chen GD
Gynecol Oncol; 2008 Mar; 108(3):533-42. PubMed ID: 18177928
[TBL] [Abstract][Full Text] [Related]
20. Comparative analysis of the expression of tenascin and established prognostic factors in human breast cancer.
Moch H; Torhorst J; Dürmüller U; Feichter GE; Sauter G; Gudat F
Pathol Res Pract; 1993 Jun; 189(5):510-4. PubMed ID: 7690952
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
